Effectiveness of fixed-dose combination of paritaprevir, ritonavir, ombitasvir, and dasabuvir in patients with chronic hepatitis C virus infection and chronic kidney diseases: real-life experiences

Ormeci N., Sezgin O., Karaali R., AYGEN B., Turan D., Yaras S., ...More

EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, vol.31, no.4, pp.534-539, 2019 (SCI-Expanded, Scopus) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 31 Issue: 4
  • Publication Date: 2019
  • Doi Number: 10.1097/meg.0000000000001334
  • Journal Name: EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.534-539
  • Keywords: hepatitis C virus, kidney diseases, PROD regimen, treatment
  • Erciyes University Affiliated: Yes

Abstract

Introduction Both hepatitis C virus infection (HCV) and chronic kidney disease (CKD) have been comorbid illnesses with increasing morbidity and mortality. The present study was conducted to present real-life experiences about treatment of HCV and CKD with a fixed-dose combination of paritaprevir 150 mg/day, ritonavir 100 mg/day as a booster, ombitasvir 25 mg/day, and dasabuvir 250 mg twice/day, the PROD regimen.